Literature DB >> 27175230

Change in prognostic factors.

D Hoelzer1, N Gökbuget1.   

Abstract

The purpose of evaluating prognostic factors in acute lymphoblastic leukemia is, first, to stratify patients into adverse- or good-risk groups, second, to determine different treatment options accordingly and, third, to evaluate their potential outcome. Prognostic factors are particularly relevant for disease-free survival and overall survival.

Entities:  

Keywords:  acute lymphoblastic leukemia; minimal residual disease; prognostic factors; risk stratification; targeted therapies

Year:  2012        PMID： 27175230      PMCID： PMC4851209          DOI： 10.1038/leusup.2012.4

Source DB:  PubMed          Journal:  Leuk Suppl        ISSN： 2044-5210


  7 in total

Review 1.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

Authors:  N Gökbuget; D Hoelzer; R Arnold; A Böhme; C R Bartram; M Freund; A Ganser; M Kneba; W Langer; T Lipp; W D Ludwig; G Maschmeyer; H Rieder; E Thiel; A Weiss; D Messerer
Journal:  Hematol Oncol Clin North Am       Date:  2000-12       Impact factor: 3.722

2.  Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.

Authors:  H M Kantarjian; S O'Brien; T L Smith; J Cortes; F J Giles; M Beran; S Pierce; Y Huh; M Andreeff; C Koller; C S Ha; M J Keating; S Murphy; E J Freireich
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

Review 3.  Modern therapy of acute lymphoblastic leukemia.

Authors:  Renato Bassan; Dieter Hoelzer
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  Risk groups in adult acute lymphoblastic leukemia.

Authors:  D Hoelzer; E Thiel; H Löffler; A Ganser; H Heimpel; T Büchner; D Urbanitz; P Koch; M Freund; H Diedrich
Journal:  Haematol Blood Transfus       Date:  1987

5.  Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults.

Authors:  D Hoelzer; E Thiel; H Löffler; H Bodenstein; L Plaumann; T Büchner; D Urbanitz; P Koch; H Heimpel; R Engelhardt
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

6.  A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

Authors:  R A Larson; R K Dodge; C P Burns; E J Lee; R M Stone; P Schulman; D Duggan; F R Davey; R E Sobol; S R Frankel
Journal:  Blood       Date:  1995-04-15       Impact factor: 22.113

7.  A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969.

Authors:  J Gaynor; D Chapman; C Little; S McKenzie; W Miller; M Andreeff; Z Arlin; E Berman; S Kempin; T Gee
Journal:  J Clin Oncol       Date:  1988-06       Impact factor: 44.544
  7 in total
  1 in total

1.  Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia.

Authors:  Hasmukh Jain; Manju Sengar; Vasu Babu Goli; Jayashree Thorat; Prashant Tembhare; Dhanlaxmi Shetty; V N Avinash Bonda; Lingaraj Nayak; P G Subramanian; Bhausaheb Bagal; Nikhil Patkar; Neha Sharma; Himanshi Gupta; Sumeet Gujral
Journal:  Blood Adv       Date:  2021-09-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.